Fenbendazole, Ivermectin & p53: Anticancer Research

Fenbendazole and Ivermectin in Cancer Care: What the Research Actually Shows

A clinical nutritionist's review of mechanisms — including p53 reactivation, microtubule disruption, glycolysis inhibition, and immune synergy — for two of the most-discussed repurposed antiparasitics in integrative oncology.

Researched and written by Keith Bishop, Integrative Cancer Educator, Cancer Coach, Clinical Nutritionist, Retired Pharmacist, and Founder of Prevail Over Cancer.

You've heard the names. A friend mentioned them. A YouTube video swore by them. A Facebook group of 100,000 members says they cured stage IV cancer. And your oncologist either rolled their eyes or warned you against them.

So what is actually true about fenbendazole and ivermectin in cancer care?

After three decades as a pharmacist and now as a clinical nutritionist and cancer coach working with patients every day, I want to walk you through what the published research actually shows — the mechanisms, the preclinical data, the human evidence, the gaps, and where these two repurposed drugs fit inside an integrative oncology framework like the Prevail Protocol™.

This is not medical advice. It is a research review. And it's the kind of review I wish every cancer patient could read before deciding what to ask their oncologist about.

Why Two Antiparasitics Are Now in Every Cancer Conversation

Drug repurposing — taking a medication approved for one disease and studying it for another — has become one of the most active areas in oncology research. The reason is simple: developing a new cancer drug from scratch costs more than a billion dollars and takes over a decade. A drug that already has decades of human safety data behind it can skip years of toxicology work.

Fenbendazole is a benzimidazole anthelmintic used in veterinary medicine since 1974. Ivermectin is a macrocyclic lactone whose discoverers won the 2015 Nobel Prize in Physiology or Medicine for its impact on parasitic diseases worldwide.

Both drugs have something else in common: a growing body of laboratory and animal research showing they interfere with multiple cancer hallmarks. Both have attracted research interest for their potential to slow cancer cell growth and boost the immune response.

The interest isn't manufactured. The peer-reviewed literature is real. But so are the gaps in human clinical evidence — and that nuance matters.

Fenbendazole: How a Veterinary Dewormer Targets Cancer Cells

Fenbendazole — abbreviated FBZ in the literature — belongs to the same benzimidazole drug class as mebendazole and albendazole, both of which are used in humans. Fenbendazole, a benzimidazole anthelmintic widely used in veterinary medicine, has garnered attention for its potential anti-tumor effects, supported by preclinical studies and anecdotal reports.

The interesting question is not whether it has anticancer activity in the lab — that's well-established. The interesting question is how.

Microtubule Disruption and Cell Cycle Arrest

Microtubules are the cellular scaffolding that pulls chromosomes apart during cell division. Disrupt them, and the cell cannot divide. In preclinical research, fenbendazole acts as a moderate microtubule-destabilizing agent, disrupting the cell cycle and triggering apoptosis or programmed cell death.

This is the same general mechanism used by taxane chemotherapies like paclitaxel and docetaxel, though fenbendazole acts at a different binding site and with different potency. In a 2025 study, FBZ dose-dependently inhibited proliferation, induced G2/M arrest, and triggered apoptosis in cervical cancer cells and cervical cancer stem cells.

p53 Reactivation: Waking Up the Guardian of the Genome

If I had to pick the single most exciting mechanism in the fenbendazole research portfolio, this would be it. And as a clinical nutritionist who works with patients on cancer prevention and reversal every day, I want you to understand why.

What is p53?

p53 is called the "guardian of the genome" for good reason. It's a tumor suppressor protein that does three critical jobs whenever a cell starts to go wrong: it halts the cell cycle to allow DNA repair, it activates DNA repair machinery directly, and — if the damage is too severe — it triggers apoptosis (programmed cell death) so the broken cell can't replicate and become a tumor.

p53 is the body's built-in cancer prevention system. And cancer almost always finds a way to disable it.

The p53 problem in cancer.

Tumor suppressor p53 is mutated in about 50% of cancers. That's a sobering statistic. But here's the part most patients don't know: in the other half of cancers, p53 itself is genetically intact — but it's been silenced by the cancer cell's defensive machinery. Most malignant melanomas carry wild-type p53, but p53 activity is often inhibited by overexpression of its negative regulators, Mdm2 or MdmX.  

Think of it like this: in roughly half of cancers, the smoke detector has been broken. In the other half, the smoke detector still works fine — but the tumor has wrapped it in a thick towel so the alarm can't sound. Wake up that p53, take off the towel, and the cell's own internal alarm system can finally do its job.

How fenbendazole activates p53.

This is where the research becomes genuinely compelling. The landmark 2018 paper from Dogra and colleagues showed exactly how fenbendazole engages p53. Fenbendazole caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, GLUT transporter expression, and hexokinase II, a key glycolytic enzyme that most cancer cells rely on. Results indicate that fenbendazole exerts its antitumor effect through disruption of microtubule dynamics, activation of p53, and modulation of genes involved in multiple cellular pathways.

That phrase — mitochondrial translocation of p53 — matters. It means fenbendazole doesn't just increase p53 levels; it actively shuttles p53 to the mitochondria, where p53 can directly initiate the cell-death cascade. This is one of the most efficient ways to kill a cancer cell, because it bypasses many of the resistance mechanisms tumors use to evade apoptosis.

A separate 2019 high-throughput screening study identified the mechanism by which benzimidazoles activate p53. Researchers performed high-throughput screening of 2448 compounds on A375 cells carrying a p53 activity luciferase reporter construct to reveal compounds that promote p53 activity in melanoma. Albendazole and fenbendazole, two approved and commonly used benzimidazole anthelmintics, stimulated p53 activity. The protein levels of p53 and p21 increased upon treatment with albendazole and fenbendazole, indicating activation of the p53-p21 pathway, while the levels of Mdm2 and MdmX decreased in melanoma and breast cancer cells overexpressing these proteins.

Translation: Fenbendazole removes the "towel" wrapped around p53 by downregulating MDM2 and MdmX, the two proteins that normally degrade p53. Less degradation means more p53. More p53 means the cancer cell faces its own internal alarm system again.

Wild-type vs. mutated p53.

This distinction is clinically important. In wild-type CRC (colorectal cancer), fenbendazole activates p53-mediated apoptosis by increasing p53 expression. The implication is that fenbendazole's p53-dependent killing mechanism may be most effective in cancers that still have functional p53 — roughly half of all cancers, including most melanomas, many breast and prostate cancers, and a substantial fraction of colorectal, ovarian, and lung cancers. 

In cancers with mutated p53, fenbendazole's other mechanisms — microtubule disruption, glucose starvation, pyroptosis — still apply. But the p53 reactivation pathway is most powerful when p53 is intact and waiting to be unleashed.

Why this matters for the broader protocol.

Within the Prevail Protocol™ framework, the p53 reactivation theme connects fenbendazole to several other foundation tools. Zinc, melatonin, vitamin D3, and sulforaphane all have published p53-supportive mechanisms. They don't work the same way fenbendazole does — they support p53 function and stability rather than triggering its mitochondrial translocation — but the convergent target is the same: restoring the genome's guardian to active duty.

This is a critical point for patients trying to understand integrative oncology. The protocol isn't a collection of random supplements stacked on top of a drug. It's a layered strategy where multiple agents converge on the same defensive pathways that the cancer has worked hard to suppress. Fenbendazole reactivates p53 acutely. Zinc, melatonin, vitamin D3, and sulforaphane keep p53 functional chronically. The combination is stronger than any single piece.

This is also why pharmaceutical companies are spending billions to develop MDM2 inhibitors as a new drug class — they're chasing the same target that fenbendazole already hits. A veterinary anthelmintic, off-patent for decades, may have been doing what Big Pharma is now racing to replicate.

Glucose Uptake and Metabolic Interference

Cancer cells are metabolically greedy. The Warburg effect — preferential glucose fermentation even in the presence of oxygen — is one of the oldest known cancer hallmarks. Fenbendazole appears to interfere with this glucose dependence, helping starve tumor cells of fuel. This is part of why metabolic strategies like Kancer Keto™ and Timed Eating for Cancer™ may be mechanistically compatible with benzimidazole therapy.

Pyroptosis: A Newer Mechanism (2025)

A 2025 paper in Frontiers in Pharmacology identified a previously undescribed mechanism. Researchers investigated the effects of FBZ on mouse mammary carcinoma cells and found that FBZ induces pyroptosis in these cells through the HK2/caspase-3/GSDME signaling pathway. Pyroptosis is an inflammatory form of programmed cell death that, unlike apoptosis, recruits the immune system to the dying tumor. That immune visibility is potentially significant for combination strategies with checkpoint inhibitors.

Dual Targeting of Cancer Stem Cells

Cancer stem cells are a small population that drives recurrence and metastasis. They survive chemotherapy and reseed the tumor. A 2025 study isolated CD133+CD44+ cervical cancer stem cells and showed that fenbendazole inhibited proliferation, induced G2/M arrest, and triggered apoptosis in both standard cancer cells and the stem cell population.

This dual targeting matters. Many conventional treatments shrink the tumor but spare the stem cells, which is why the cancer comes back.

Ivermectin: A Nobel-Prize-Winning Drug With Multi-Pathway Anticancer Activity

Ivermectin's anticancer mechanisms are arguably even broader than those of fenbendazole. Unlike conventional chemotherapy agents that typically target a single pathway, ivermectin acts as a "multi-targeted" drug, simultaneously affecting multiple cancer hallmarks.

PAK1/Akt/mTOR Axis

PAK1 (p21-activated kinase 1) is a hub kinase that drives proliferation, invasion, and survival in many cancers. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Inhibit PAK1, and you knock out signaling for multiple downstream pathways at once. Mechanistically, ivermectin strongly inhibits the expression of PAK1 and promotes PAK1 degradation through the proteasome-dependent pathway in esophageal squamous cell carcinoma.

WNT/β-Catenin and Cancer Stem Cells

The WNT pathway is one of the master regulators of cancer stem cell self-renewal. Ivermectin inhibits the Wnt signaling pathway associated with epithelial-to-mesenchymal transition in endocrine-resistant breast cancer cells undergoing metastasis. EMT — the process by which a cancer cell sheds its identity and becomes mobile — is how tumors metastasize. Blocking WNT blocks EMT. Blocking EMT may block metastasis.

Immune Checkpoint Synergy

This may be the most clinically actionable mechanism. Preclinical models suggest that ivermectin can enhance the activity of immune checkpoint inhibitors, potentially overcoming resistance in hard-to-treat cancers. Ivermectin appears to convert "cold" tumors — tumors that the immune system ignores — into "hot" tumors that immunotherapy can recognize and attack.

Multi-Cancer Activity

The breadth of ivermectin's preclinical anticancer activity is striking. Extensive in vitro and animal studies demonstrate ivermectin's anticancer activity across multiple cancer types: breast cancer through PAK1/Akt/mTOR pathway blockade, lung cancer through autophagy and apoptosis induction, colorectal cancer through WNT-TCF signaling blockade, hepatocellular carcinoma through mTOR/STAT3 pathway inhibition, pancreatic cancer with synergy when combined with metabolic therapies, and ovarian cancer through PAK1 inhibition. 

The Case for Combination: Why Mechanisms Overlap and Diverge

Patients ask me constantly whether they should choose between fenbendazole and ivermectin. The honest mechanistic answer is that they target different cancer hallmarks, and there is theoretical and observational rationale for combining them.

Fenbendazole hits the cytoskeleton and tumor metabolism. Ivermectin hits oncogenic signaling and the immune microenvironment. The hypothesis is that the combination addresses more of the cancer's defense system than either drug alone.

Another notable discovery was the apparent synergy between fenbendazole and ivermectin. Cases in which both agents were used, especially in TNBC, showed higher response rates than with fenbendazole alone. This aligns with recent mechanistic reviews suggesting that ivermectin can inhibit key cancer pathways, such as STAT3 and Wnt/TCF, and may enhance the anticancer effects of microtubule-disrupting agents, such as fenbendazole.

A 2026 systematic review framed the combination as follows: Preclinical studies demonstrate complementary mechanisms of action across all three agents—ivermectin, fenbendazole, and mebendazole. Dual-agent studies show additive effects; triple-agent synergy has not been systematically quantified.

Translation: there's a biological reason to believe combination is better than monotherapy, but we don't yet have the rigorous trials to quantify by how much.

Human Evidence: Case Reports, Clinical Trials, and What's Still Missing

This is where intellectual honesty matters most. The preclinical evidence is genuinely strong. The human evidence is genuinely incomplete. Both statements are simultaneously true.

Anecdotal Series and the Joe Tippens Story

The modern fenbendazole-for-cancer movement traces back to Joe Tippens, a small-cell lung cancer patient given three months to live who attributes his complete remission to a self-administered protocol built around fenbendazole. Since then, a review of 170 anecdotal reports from 2023 to 2025 noted tumor regression and remission across various cancers, though these lacked clinical rigor. Social media platforms, including Facebook groups with over 100,000 members, amplify these claims, driving off-label use.

In December 2025, three of these anecdotal cases were published in the peer-reviewed literature. A case series was published in Case Reports in Oncology covering metastatic breast cancer in an 83-year-old woman, stage IV prostate cancer in a 75-year-old man, and BRAF-positive malignant melanoma in a 63-year-old male. (Note: This Karger paper was later flagged with a retraction notice. The cases themselves remain in the public record, but readers should know the peer-reviewed publication was withdrawn.)

For ivermectin, a 2026 case series reviewed 16 head and neck cancer patients treated with fenbendazole and ivermectin, with preclinical mechanisms including microtubule disruption, inhibition of oncogenic signaling, metabolic interference, and induction of apoptosis proposed as the rationale.

These case reports are valuable signals. They are not proof. All are uncontrolled and confounded by prior or concurrent therapies. A patient who responds may be responding to the ivermectin, the fenbendazole, the chemotherapy they're also receiving, the changes they made to their diet, or the placebo effect. We cannot disentangle these factors from a case report.

The MD Anderson Trial

The single most important human study in this space is an actual clinical trial. A phase II trial is studying the side effects and best dose of ivermectin in combination with pembrolizumab in patients with triple-negative breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack cancer, and co-administering ivermectin with pembrolizumab may increase pembrolizumab's effect in shrinking tumors.

The trial structure is informative. Participants receive ivermectin orally on days 1-3, 8-10, and 15-17, and balstilimab or pembrolizumab intravenously on day 1 of each 21-day cycle, for up to 35 cycles or 2 years.

That pulsed dosing — 3 days on, 4 days off — closely mirrors the cycling pattern used in the Modified Joe Tippens Foundation within the Prevail Protocol™. It is also strikingly aligned with the 5-on/2-off weekly cycling I use across all therapeutic herbs and repurposed medications in my client guides. The trial designers landed there independently, and that convergence is meaningful.

What's Still Missing

What we do not have for either drug is a completed randomized controlled trial demonstrating an overall survival benefit in a defined cancer population. The lack of human clinical data, pharmacokinetic challenges, and risks of unsupervised use necessitate rigorous trials to validate efficacy, optimize delivery, and ensure safety.

We have a mechanism. We have case reports. We have ongoing trials. We do not yet have definitive proof. Anyone telling you otherwise — in either direction — is overstating the evidence.

Safety, Quality, and Sourcing Considerations

Both drugs have decades of safety data in their approved uses. That is one of the things that makes them attractive for repurposing. But cancer-use scenarios — higher doses, longer durations, and combination with chemotherapy or targeted therapy — are not what the original safety data covered.

Drug-Drug and Drug-Nutrient Interactions

This is where my training as a pharmacist matters most. Both fenbendazole and ivermectin interact with cytochrome P450 enzymes — particularly CYP3A4. That means they can theoretically alter the metabolism of many chemotherapies, targeted agents, and even common supplements. Specific interactions worth flagging:

• Ivermectin and CYP3A4 substrate chemotherapies — close monitoring required.
• Fenbendazole and concurrent steroids — steroids may blunt some of fenbendazole's effects.
• Both drugs and immunomodulators — overlapping immune effects need supervision.
• Ivermectin and warfarin — bleeding risk consideration.

This is not a self-administered project. It is an integrative oncology project that requires a clinician who understands both conventional treatment and the pharmacology of repurposed drugs.

Quality and Sourcing

Pharmaceutical-grade material exists. Veterinary-grade material is not the same as pharmaceutical-grade. Compounded human preparations from licensed compounding pharmacies offer middle-ground access, but the regulatory landscape varies by state and country. Sourcing matters, and not all sources are equivalent in purity, potency, or labeling accuracy.

How Fenbendazole and Ivermectin Fit the Prevail Protocol™

Within my Prevail Protocol™ framework, repurposed medications occupy a defined slot — not the foundation, but a layer of the integrative strategy that supports it. The Modified Joe Tippens Foundation has been merged with my ONCO-ADJUNCT™ Pathways into a single foundation block, with cycling principles applied consistently across the entire therapeutic stack.

The p53 convergence is intentional. Several POC Protocol foundation supplements — zinc, melatonin, vitamin D3, sulforaphane — also support p53 function. When fenbendazole acutely reactivates p53, the foundation stack helps sustain that activation between dosing windows. This is the kind of mechanistic layering that turns a single repurposed drug into a coordinated integrative strategy.

For both fenbendazole and ivermectin in my framework:

• Cycling is the default. 5 days on, 2 days off weekly, extending to a 3-day skip around chemotherapy infusions. This pattern reduces tolerance, allows the body to recover windows, and aligns with how the MD Anderson trial pulses ivermectin.
• No dosage information is provided in my client-facing materials. Dosing belongs in a one-on-one clinical relationship with a qualified prescriber, not in a public blog post or guide.
• Foundation supplements come first. D3/K2, krill oil, vitamin C, sulforaphane, AHCC, beta-glucan, the broader POC Protocol supplement list, and the metabolic foundations of Kancer Keto™, Timed Eating for Cancer™, and the Palm Rule are built before any repurposed medications are layered in.
• Pillar integration. Repurposed meds touch the Integrate Every System pillar of the Seven-Pillar PREVAIL™ framework. They do not replace Root Your Nutrition, Elevate Your Defenses, or Live With Purpose. A drug strategy without nutrition, immune support, sleep, movement, stress regulation, and faith is incomplete.

The patients who do best, in my coaching experience, are not the ones who chase a single agent as a magic bullet. They are the ones who build the full foundation and then thoughtfully layer in tools like fenbendazole or ivermectin under qualified supervision.

Work With Me

If you're navigating a cancer diagnosis and wondering how repurposed medications, evidence-based supplements, nutrition strategy, and your conventional treatment plan all fit together, you don't have to figure it out alone.

• POC Learning Center — Free and paid educational content on integrative oncology, the Prevail Protocol™, and the Seven-Pillar PREVAIL™ framework. Visit the Learning Center
• POC Academy — Deep-dive courses for patients, caregivers, and practitioners. Explore the Academy
• One-on-One Cancer Coaching — Personalized coaching to build your protocol and integrate it with your oncology care. Book a Free Initial 15 - Minute Consultation
• YouTube — @prevailovercancer — New research videos every week. Subscribe to YouTube
• Podcast Playlist — All episodes in one place. Listen to the Podcast Playlist

Supplement Resources:

• UltraBotanica ONCO-ADJUNCT™ Pathways — code PREVAIL20 — prevailovercancer.com/pathway
• Designs for Health (10% off) — prevailovercancer.com/Designs-for-Health-Supplements
• Fullscript (10% off) — prevailovercancer.com/fullscript-supplements
• Flourish Nutrition Assessment Pack — code PREVAIL5 — flourishrx.com/products/nutrition-assessment-pack

Lab Testing:

• Rupa Health — labs.rupahealth.com/store/storefront_64e2oDG
• Ulta Labs Cancer Screening Panel — ultalabtests.com/partners/prevailovercancer
• Myriad MyRisk Genetic Testing - MyRisk
• 3x4 Genetics — 3x4genetics.com

Together — We Prevail Over Cancer!™

Prevail. Assess. Don't Guess.™

References

1. Lee JS, et al. Fenbendazole exhibits differential anticancer effects in vitro and in vivo in models of mouse lymphoma. Cancer Reports. 2025. PubMed
2. Nguyen J, et al. Oral fenbendazole for cancer therapy in humans and animals. Anticancer Research. 2024;44(9):3725-3735. PubMed
3. Dogra N, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8(1):11926. PubMed
4. Pan Y, et al. Fenbendazole exhibits antitumor activity against cervical cancer through dual targeting of cancer cells and cancer stem cells. Molecules. 2025;30(11):2377. PubMed
5. Liu Y, et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway. Frontiers in Pharmacology. 2025;16:1596694. PubMed
6. Makis W, Baghli I, Martinez P. Fenbendazole as an anticancer agent? A case series of self-administration in three patients. Case Reports in Oncology. 2025;18(1):856-863. PubMed (Note: retracted)
7. Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research. 2021;163:105207. PubMed
8. Dou Q, Chen HN, Wang K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Research. 2016;76(15):4457-4469. PubMed
9. Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discovery & Therapeutics. 2009;3(6):243-246. PubMed
10. Nambara S, Masuda T, Nishio M, et al. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget. 2017;8(64):107666-107677. PubMed
11. Wang J, Xu Y, Wan H, Hu J. Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress. Biochemical and Biophysical Research Communications. 2018;497(1):241-247. PubMed
12. Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. Journal of Experimental & Clinical Cancer Research. 2019;38(1):265. PubMed
13. Rujimongkon K, Adchariyasakulchai P, Meeprasertskul P, Ketchart W. Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells. PLOS One. 2025;20(6):e0326742. PubMed
14. Draganov D, et al. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Precision Oncology. 2021;5:8. PubMed
15. ClinicalTrials.gov. Ivermectin and pembrolizumab for the treatment of metastatic triple negative breast cancer. NCT05318469. ClinicalTrials.gov
16. Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research. 2018;8(2):317-331. PubMed
17. Crump A, Ōmura S. Ivermectin, "wonder drug" from Japan: the human use perspective. Proceedings of the Japan Academy, Series B. 2011;87(2):13-28. PubMed
18. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8(1):11926. doi:10.1038/s41598-018-30158-6. PubMed
19. Králová V, Hanušová V, Staňková P, et al. Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells. Molecules. 2019;24(11):2152. doi:10.3390/molecules24112152. PubMed
20. Nguyen J, Naidoo D, Cohen J. Oral fenbendazole for cancer therapy in humans and animals. Anticancer Research. 2024;44(9):3725-3735. doi:10.21873/anticanres.17199. PubMed
21. Yu Y, Tang Y, Yang J, et al. Therapeutic potential of p53 reactivation in cervical cancer. Critical Reviews in Oncology/Hematology. 2021;157:103182. doi:10.1016/j.critrevonc.2020.103182. PubMed
22. Phan TTT, Lin YC, Chou YT, et al. Tumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics. Oncogenesis. 2022;11(1):26. doi:10.1038/s41389-022-00401-x. PubMed

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. The information in this blog post is provided for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Fenbendazole is an FDA-approved veterinary anthelmintic and is not FDA-approved for cancer treatment in humans. Ivermectin is FDA-approved for specific parasitic infections in humans and is not FDA-approved for cancer treatment. Use of either medication outside of approved indications is considered off-label and may carry risks including drug interactions, organ toxicity, and interference with conventional cancer treatments. Always consult with your qualified oncology team and a clinician familiar with integrative oncology before considering any repurposed medication. Never discontinue conventional cancer treatment without your oncologist's guidance.

© 2026 Keith Bishop, Prevail Over Cancer LLC. All rights reserved.

prevailovercancer.com